Genprex(GNPX)盘前涨121.19% 昨日收涨265.62% 已完成Acclaim-3临床试验第1期剂量递增

金吾财讯
22 Oct 2024

金吾财讯 | 基因治疗公司Genprex(GNPX)盘前大幅上涨,截至发稿,涨121.19%,报3.35美元,此前曾一度涨超145%。此外,需要注意的是,该股昨日收涨265.62%。消息面上,Genprex宣布已完成Reqorsa基因疗法(quaratusugene ozeplasmid)联合Tecentriq(atezolizumab)用于广泛期小细胞肺癌(ES-SCLC)患者维持治疗的Acclaim-3临床试验第1期剂量递增部分的0.09mg/kg剂量组。此外,安全审查委员会(SRC)已批准将剂量递增至最高剂量组0.12 mg/kg。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."